Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials.
Tahereh FarkhondehAlireza AmirabadizadehHamed AramjooSilvia LlorensBabak RoshanravanFarhad SaeediMarjan TalebiMehdi ShakibaeiSaeed SamarghandianPublished in: Current oncology (Toronto, Ont.) (2021)
Patients with operable breast and endometrial cancer under metformin therapy showed no significant changes in the investigated metabolic biomarkers in the most of included study. It was also found that metformin could decrease Ki-67 in patients with operable endometrial cancer. In comparison to the results obtained of our meta-analysis, due to the high heterogeneity and bias of the included clinical trials, the present findings could not confirm or reject the efficacy of metformin for patients with breast cancer and endometrial cancer.
Keyphrases
- endometrial cancer
- clinical trial
- systematic review
- papillary thyroid
- type diabetes
- phase ii
- squamous cell carcinoma
- meta analyses
- randomized controlled trial
- radiation therapy
- mass spectrometry
- squamous cell
- rectal cancer
- wound healing
- bone marrow
- phase iii
- study protocol
- double blind
- high resolution
- replacement therapy
- mesenchymal stem cells
- lymph node metastasis